SINDA BIOPHARMACEUTICAL CO., LTD. (“SINDA BIO”) RELEASED AN INSIDE STATEMENT ON APRIL 30, 2024, ANNOUNCING THAT ITS FIRST QUARTER 2024 PRODUCT REVENUE EXCEEDED RMB17 BILLION, ACHIEVING A YEAR-ON-YEAR GROWTH OF MORE THAN 60%. The company noted that this result was due to the rapid growth of its product portfolio, particularly strong sales and market leadership of Dabersho® (Cindlyone Anti-Injection), as well as the accelerated growth of new products. Sinda Biologics is dedicated to the development of the oncology field and integrated product lines. Currently, 10 products have been approved and several new drugs are in development at different stages. The company said the diversity of its innovation pipeline and the market potential will provide a solid foundation for long-term sustainable growth. The financial information is compiled on the basis of internal management records and is not reviewed or reviewed by external auditors.

SINDA BIOPHARMACEUTICAL CO., LTD. (“SINDA BIO”) RELEASED AN INSIDE STATEMENT ON APRIL 30, 2024, ANNOUNCING THAT ITS FIRST QUARTER 2024 PRODUCT REVENUE EXCEEDED RMB17 BILLION, ACHIEVING A YEAR-ON-YEAR GROWTH OF MORE THAN 60%. The company noted that this result was due to the rapid growth of its product portfolio, particularly strong sales and market leadership of Dabersho® (Cindlyone Anti-Injection), as well as the accelerated growth of new products. Sinda Biologics is dedicated to the development of the oncology field and integrated product lines. Currently, 10 products have been approved and several new drugs are in development at different stages. The company said the diversity of its innovation pipeline and the market potential will provide a solid foundation for long-term sustainable growth. The financial information is compiled on the basis of internal management records and is not reviewed or reviewed by external auditors.